**Biotechnological Transformation of Artemisinin: Toward an Effective Anti-Malaria Drug**

MUHAMMAD NOR OMAR¹, NOR HAZWANI M. HASALI¹, NAIK T. KHAN², SYED FARAZ MOIN² and HELMI Y. ALFARRA¹

¹Department of Biotechnology, Kulliyyah of Science, International Islamic University Malaysia, (Malaysia)
²International Center for Chemical and Biological Sciences, University of Karachi, Karachi (Pakistan).

(Received: February 20, 2012; Accepted: March 25, 2012)

**ABSTRACT**

In recent years, artemisinin (1) has remained an effective drug to treat malaria. Numerous approaches have been adapted to increase the efficacy of (1) against antibiotic resistant malarial parasite. Microbial biotransformation of (1) has been used recently to produce promising derivatives of (1) on a large scale with low costs. During the last decade several biotransformation studies on (1), by using microorganisms, have been reported. This literature review focuses on the most recent microbial transformation studies on artemisinin and its derivatives.

**Key words:** Artemisinin, Malaria, Biotransformation, Microorganisms, Hydroxylation.

**INTRODUCTION**

Biotransformation involves the chemical transformation of substrates to desired products by using enzymes, either purified or crude, from microorganisms (bacteria and fungus), plants or animals¹². Transformation of compounds by the application of whole cell microorganisms is often advantageous as compared to isolated enzymes⁸. These days, microbial transformation is considered to be the inexpensive and ecologically competitive technology for the biotechnological specialists in looking for new methods to produce pure useful chemicals, pharmaceutical, and agrochemical compounds⁶. Microbial transformation has been extensively used, to create new and useful metabolites of almost all classes of terpenes, as a substitute of chemical synthesis for preparation of pharmacologically active compounds⁹.

The current review focuses on the microbial transformation of artemisinin (1) during the recent time. Scifinder research tool was used to screen the literature of this related subject, and to the best of our knowledge, this is the first review about the microbial biotransformation of (1).

**Artemisinin versus malaria**

**Therapeutic importance**

Malaria has been a universal health problem which kills millions of people every year out of more than 300 million cases in the world. About 20% of childhood deaths in tropics are claimed to be due to malaria⁴⁻⁵. In Africa, the disease has killed at least one child in every 30 seconds (WHO). *Plasmodium falciparum* species is the most common cause of cerebral malaria. The continuously developing resistance of the malaria parasite to the anti-malarial drugs and the absence of successful anti-malarial vaccine challenged the researcher for the development of efficient anti-malarial drugs to treat this infection. The World Health Organization (WHO) considers artemisinin (1) (figure 1) and its derivatives as part of the best approach for malaria in Africa and South/east Asia⁶⁻⁸⁻¹⁰. At present (1) has become the most effective way to deal with resistant strains of *P. falciparum* chloroquine and mefloquine with minor side effects⁶⁻⁸. Moreover, (1) also shows effectiveness against other parasites in addition to some viral infections. Furthermore, (1) can be used in treatment of hepatitis B plus some cancer cell lines such as human leukaemia, breast and colon cancer⁶⁻⁸.
Source of Artemisinin

Artemisinin, also known as qinghaosu, was isolated, in 1970s, from glandular trichomes of the herbal plant *Artemisia annua* Linn by Chinese researchers, and was identified as a sesquiterpene lactone endoperoxide. Artemisinin was found only in *A. annua* with amount of 0.01% to 1.4% in some cultivated strains. Recently (1) has been reported in other *Artemisia* species which are *A. bushriences* and *A. dracuculus var dracunculus* with different traces. *A. annua* has become an attractive supply of essential oils, while its commercial significance comes from the probability of being the only source of genus *Artemisia* to synthesize (1). Although, cost of (1) may be one of important restrictions for users of anti-malaria, it has been comprehensively reviewed that there are certain natural problems with current artemisins that require discussion. It was reviewed that (1) based drugs (e.g., artemether and arteether) have neurotoxic and cardiotoxic effects in experimental animals, however, millions of doses in various formulations have been given to humans without significant evidence of major toxicity. Artemisinin is relatively easily purified by crystallisation after extraction from *A. annua* plants but is extremely difficult to synthesise de novo. The disadvantage of (1) is that it cannot be administered orally or by rectal route. It can only be given via internal route because it is a highly crystalline compound that does not dissolve in oil or water. Semisynthetic derivatives of (1) i.e Artesunate, Artemether, Arteether, Dihydroartemisinin, artesunic acid and Artelinic acid have been chemically modified at the C10 position to overcome that problem.

Mode of action

Artemisinin and its analogues induce a very rapid reduction of blood parasites, starting almost directly after administration. The antimalarial action of (1) and its derivatives has been accredited to their chemical ability to produce free radicals. This approach of action has been suggested partially on the argument that, well standard sources of free radicals (such as tert-butylperoxide) can eradicate malaria parasites. Free radicals can be generated from peroxides in the presence of Fe^{2+} as catalyst. Carbon centred free radicals have been placed forward as principal intermediates in the process of killing the parasite, another mechanism for artemisinins, based on reserve of the malarial parasite’s calcium ATPase (sarcoplasmic endoplasmic reticulum calcium ATPase, SERCA) has been suggested. Artemisinin has been shown to be involved in alkylation of proteins containing heme group like hemoglobin, catalase and cytochrome c. The action of (1) at least in part is reported to be conducted by interference in haemoglobin catalysis inside the parasite. Artemisinin inhibit the heme polymerization by histidine rich protein II of *Plasmodium falciparum*. The hemozoin (malarial pigment) produced by the mature parasite were also broken down by (1). It has been found that monoalkylated and dialkylated haem derivatives produced by (1) can bind to histidine rich protein II and inhibit hemozoin formation. On the other hand generation and accumulation of these alkylated haemoglobin can bring about the death of parasite.

Microbial transformation of Artemisinin

The scaling up production of artemisinin (1) from *A. annua* L. becomes the biggest challenge faced by researchers who are competing to find a potent drug against multi-drug resistant strain of malaria. In recent years, the chemical synthesis of artemisinin is not promising that much thus, biotransformation has been used as an option to produce it commercially and in large scales through modern biotechnology process. Sensitive nature, high recur rate, oil and water insolubility of (1) are disadvantages which limits its transformation by using extensive chemicals to develop a strong antimalarial derivatives. Isomeric, rearranged, hydrolyzed and reduced products are all promising results of microbial transformation of (1) and its analogues. Furthermore, microbial transformations can be used to study mammalian metabolic pathways as it is reported in some successful studies which predicting the drug metabolism in mammals. Processes that can be involved in the biotransformation reactions of (1) include hydration reactions and breakdown of heterocyclic rings, hydroxylation of methyl, methyne and methylene group deoxidation reactions. *Aspergillus niger*, the most common species of the genus *Aspergillus* which causes black mold disease on fruits and vegetables,
transformed Artemisinin (1) into 1α-hydroxydeoxyartemisinin (2), deoxyartemisinin (3), 3β-hydroxydeoxyartemisinin (4) with yield 15%, 2β-hydroxyartemisinin (5) with 80% yield and with 19% yield of 9 β-hydroxyartemisinin (6)\textsuperscript{19,21,22}. 18 et al., 2002a found 3 in the substrate controls without any microorganisms, which indicated that 3 was not a biotransformed product but a product of chemical reaction catalyzed by Fe\textsuperscript{2+} in the potato medium. A. flavus was also reported to transform 1 to 3\textsuperscript{20}. A. flavipes, A. flavipes and A. parasiticus were also screened for the metabolism of 1, but there were no metabolites recorded from these species.

Cunninghaamella species have been used to metabolize a diverse range of drugs in a manner similar to that in mammals; these are thus used as microbial models for studying mammalian drug metabolism. Moreover, these fungi are also attractive to the researchers due to their ability to transform bioactive compounds. Contrary to Aspergillus, Cunninghaamella echinulata transformed 1 into a novel metabolite 10α-hydroxyartemisinin (7) with 50% yield\textsuperscript{19}. Cunninghaamella elegans, on the other hand, transformed 1 into 9β-hydroxy-11α-artemisinin (8) as a minor metabolite with yield 6% along with 4, 6 with 5.4%, 6.5% correspondingly and 7 which considered as the major metabolite with yield of 78.6%\textsuperscript{23}. Interestingly C. elegans gave 8 which was characterized by the inversion of stereochemistry at C-11. Cunninghaamella blakesleena was also screened for its ability to transform (1), but no transformation was obtained\textsuperscript{24}.

As a final point, more than 40 species of microorganisms have been reported to transform Artemisinin; only 11 of them have been used for complete transformation while 29 have been used only for preliminary screening. Mucor polymorphous reported to transform (1) to (6), 3β-hydroxyartemisinin (9), (3) and 3β-hydroxydeoxyartemisin (10)\textsuperscript{21}, while Williamson et al., 2007 reported three different culture collections of Mucor\textsuperscript{25}. rammanianus to transform (1) to (4), (6), (7) and (8) with a relative variety of yields according to the variation of the culture
collection type, in addition to that *Mucor mucedo* was used to transform the same substrate but there was no metabolites recorded\(^{25}\).

Although that there are five different species of *Streptomyces* have been used to transform (1), only one species – *Streptomyces griseus* – has been reported to provide four different metabolites they were (4) with 9.5%, (6) with 16.1%, Artemisitone-9 (11) with 12.5% and 9\(\beta\)-hydroxyartemisinin\(^{12}\) with 16.5% \([25]\). Lately Goswami et al., 2010 have reported two different compound that have not been reported from the transformation of (1) by using *Penicillium simplicissimum* these two compounds described as 3\(\beta\)-acetoxyartemisinin\(^{13}\) with 20.6% and 3\(\beta\)-hydroxyartemisinin\(^{14}\) with 31.3%, as well in 1989 another species of *Penicillium* which is *Penicillium chrysogenum* has been used by Lee et al,1989. and they reported for the first time the compounds (3) and (4). *Eruotium amstelodami* transformed (1) to (5) and (6) with yields 63% and 32% respectively\(^{23}\), and the only *Nocardia corallina* species of this genus was used by Lee et al., 1989 to give (3).

Furthermore, many studies report the conversion of Artemisinin derivatives by microorganisms including conversion of 10-deoxyartemisinin to 5\(\beta\)-hydroxy-10-deoxyartemisinin, 4\(\beta\)-hydroxy-1,10-deoxoartemisinin, and 7\(\beta\)-hydroxy-10-deoxoartemisinin by *C. elegans*\(^{27}\); hydroxylation of 10-deoxoartemisinin to 15-hydroxy-10-deoxoartemisinin by *Aspergillus niger*\(^{28}\); 10-deoxoartemisinin to 7\(\beta\)-hydroxy-10-deoxyartemisinin by *M. rammanianus*\(^{29}\); conversion of artemisitene to 7\(\beta\)-hydroxy-9-epi-artemisinin by *Aspergillus niger*\(^{28}\); conversion of arteether to 7\(\beta\)-hydroxyartemether by *Streptomyces lavendulae*\(^{30}\); conversion of arteether to 7\(\beta\)-hydroxyartemether by *C. elegans*\(^{32}\) and *Beauveria sulfurescens*\(^{34}\).

Antimalarial activities of more than 14 transformed metabolites of artemisinin and its derivatives that have been reported in this literature were evaluated, however, none of these metabolites have found superior in antimalarial activity to that of the original substrate.

**Concluding remarks**

To date, artemisinin has been obtained commercially from the cultivation of *A. annua* which makes it costly. As a result, there is a great need for better financial system pop up to produce artemisinin based drugs. Undoubtedly, any upgrading by conventional breeding is likely to lower the cost of artemisinin production. Depending on regulatory and related costs, biotransformation of artemisinin is still a promising opportunity that may help to produce novel derivatives. It is also much cheerful to observe the commercial significance in this area in the form of Dafra Pharma International. It was reported that microbial-derived (1) combination therapies might reduce the cost of the therapy from 30%-60% which might give a reasonable prices for artemisinin base combination therapy (ACT).

Artemisinin and its derivatives can be safe and well-tolerated antimalarial drugs. However, they can be inadequate to treat malaria as monotherapy, hence, moments should be invested in discovering more effective derivatives of (1) to a part of combination therapy for multidrug resistant malaria. On our ongoing research we are screening microorganisms that have not been used before as in the hope to find novel microorganisms that might produce novel bioactive metabolites of artemisinin.

**ACKNOWLEDGEMENTS**

We would like to thank International Islamic University who is supporting our research and Mr. Omar Alqatami who supported us with some of the published materials.

**REFERENCES**

2. Baiping, M., Bing, F., Hongzhi, H., Yuwen C.


